Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same author

Artificial intelligence-enabled liquid biopsy in cancer: a systematic review and meta- analysis of diagnostic performance and biological implications.

Frontiers in oncology·2026
Same author

Genome-wide SNP-based Profiling of Loss of Heterozygosity Reveals Distinct Molecular Subgroup-specific Patterns in Gastrointestinal Stromal Tumors (GIST).

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Handling missing modalities in multimodal survival prediction for non-small cell lung cancer.

NPJ digital medicine·2026
Same author

Risk factors and causes of early death in germ cell tumors: a Global Society for Rare GU tumors study.

British journal of cancer·2026
Same author

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026

Related Experiment Video

Updated: Jun 16, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Cetuximab: from bench to bedside.

Bruno Vincenzi1, Alice Zoccoli, Francesco Pantano

  • 1Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy. b.vincenzi@unicampus.it

Current Cancer Drug Targets
|January 22, 2010
PubMed
Summary
This summary is machine-generated.

Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), inhibiting tumor cell growth and approved for colorectal and head and neck cancers. It shows efficacy through various mechanisms including antibody-dependent cellular cytotoxicity.

More Related Videos

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Related Experiment Videos

Last Updated: Jun 16, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids

Published on: June 14, 2021

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Cetuximab is a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
  • It inhibits EGFR signaling pathways, affecting cell proliferation, apoptosis, and angiogenesis.
  • Cetuximab also mediates antibody-dependent cellular cytotoxicity (ADCC).

Purpose of the Study:

  • To review the pre-clinical and clinical data on Cetuximab's biological properties.
  • To focus on predictive markers of clinical response to Cetuximab therapy.

Main Methods:

  • Review of in vitro and in vivo experimental data.
  • Analysis of numerous clinical trials in various cancer types.
  • Examination of FDA-approved indications and treatment regimens.

Main Results:

  • Cetuximab inhibits EGFR-expressing tumor cell growth.
  • Demonstrated efficacy in metastatic colorectal cancer (mCRC) and head and neck squamous cell carcinoma (HNSCC).
  • Approved for mCRC and HNSCC, often in combination therapies.

Conclusions:

  • Cetuximab possesses diverse anti-cancer properties, including direct kinase inhibition and ADCC.
  • Clinical efficacy is established in specific cancer types, with ongoing research into predictive markers.
  • Further understanding of its biological actions can optimize therapeutic strategies.